Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, March 4, 2022
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
[ Fri, Mar 04th 2022
] - WOPRAI
Keay Nakae Maintained (ABUS) at Strong Buy with Increased Target to $6 on, Mar 4th, 2022
Keay Nakae of Chardan Capital, Maintained "Arbutus Biopharma Corporation" (ABUS) at Strong Buy with Increased Target from $5.5 to $6 on, Mar 4th, 2022.
Keay has made no other calls on ABUS in the last 4 months.
There are 2 other peers that have a rating on ABUS. Out of the 2 peers that are also analyzing ABUS, 0 agree with Keay's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Keay
- Dennis Ding of "Jefferies" Upgraded from Hold to Strong Buy and Increased Target to $5 on, Wednesday, February 2nd, 2022
- Jason Butler of "JMP Securities" Maintained at Buy with Increased Target to $9 on, Monday, November 8th, 2021
